The enzyme-modified comet assay: Enzyme incubation step in 2 vs 12-gels/slide systems.


Journal

Mutation research. Genetic toxicology and environmental mutagenesis
ISSN: 1879-3592
Titre abrégé: Mutat Res Genet Toxicol Environ Mutagen
Pays: Netherlands
ID NLM: 101632149

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 09 08 2018
revised: 09 10 2018
accepted: 18 11 2018
entrez: 29 9 2019
pubmed: 29 9 2019
medline: 24 3 2020
Statut: ppublish

Résumé

The enzyme-modified comet assay is a commonly used method to detect specific DNA lesions. However, still a lot of errors are made by many users, leading to dubious results and even misinterpretations. This technical note describes some critical points in the use of the enzyme-modified comet assay, such as the enzyme concentration, the time of incubation, the format used and the equipment. To illustrate the importance of these conditions/parameters, titration experiments of formamidopyrimidine DNA glycosylase (Fpg) were performed using the 2 gels/slide and the 12 minigels/slide formats (plus the 12-Gel Comet Assay Unit™). Incubation times of 15 and 30 min, and 1 h were used. Results showed that the 12 minigels/slide system requires a lower volume and concentration of Fpg. A longer time of incubation has a bigger impact when using such format. Moreover, the paper describes how to perform and interpret a titration experiment when using the enzyme-modified comet assay.

Identifiants

pubmed: 31561901
pii: S1383-5718(18)30309-7
doi: 10.1016/j.mrgentox.2018.11.005
pii:
doi:

Substances chimiques

Alkylating Agents 0
Gels 0
8-Hydroxy-2'-Deoxyguanosine 88847-89-6
DNA-Formamidopyrimidine Glycosylase EC 3.2.2.23

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

402981

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Damian Muruzabal (D)

Department of Pharmacology and Toxicology, University of Navarra, C/Irunlarrea 1, 31009 Pamplona, Spain. Electronic address: dmuruzabal@alumni.unav.es.

Sabine A S Langie (SAS)

VITO-Sustainable Health, Boeretang 200, 2400 Mol, Belgium; Centre for Environmental Sciences, Hasselt University, Diepenbeek, Belgium. Electronic address: sabine.langie@vito.be.

Bertrand Pourrut (B)

ISA Lille - LGCgE, University of Lille Nord de France, 48 boulevard Vauban, 59046 Lille, France. Electronic address: bertrand.pourrut@yncrea.fr.

Amaya Azqueta (A)

Department of Pharmacology and Toxicology, University of Navarra, C/Irunlarrea 1, 31009 Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Spain. Electronic address: amazqueta@unav.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH